{"id":"dor-3tc-tdf","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Renal impairment (TDF-related)"},{"rate":null,"effect":"Bone density loss (TDF-related)"}]},"_chembl":{"chemblId":"CHEMBL48518","moleculeType":"Small molecule","molecularWeight":"327.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase. Lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) that are incorporated into the growing viral DNA chain, causing chain termination. Together, these three agents suppress HIV replication by targeting reverse transcriptase through complementary mechanisms.","oneSentence":"DOR/3TC/TDF is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: reverse transcriptase inhibition and nucleotide reverse transcriptase inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:53.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"}]},"trialDetails":[{"nctId":"NCT04375800","phase":"PHASE2","title":"Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-03","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":84},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT07075146","phase":"PHASE3","title":"DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-05-05","conditions":"HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity","enrollment":306},{"nctId":"NCT06034938","phase":"PHASE2","title":"DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)","status":"RECRUITING","sponsor":"University Hospital, Caen","startDate":"2024-02-08","conditions":"Hiv","enrollment":32},{"nctId":"NCT04665375","phase":"PHASE4","title":"Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2021-04-26","conditions":"Hiv, Weight Gain","enrollment":4},{"nctId":"NCT05924438","phase":"PHASE3","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-11-08","conditions":"HIV-1-infection","enrollment":600},{"nctId":"NCT05477407","phase":"NA","title":"Adipose Tissue After Switch to Doravirine","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT04433780","phase":"PHASE3","title":"DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2021-01-04","conditions":"HIV-1-infection","enrollment":133},{"nctId":"NCT05457530","phase":"PHASE3","title":"Doravirine and Weight Gain in Antiretroviral Naive","status":"WITHDRAWN","sponsor":"Prism Health North Texas","startDate":"2022-08-01","conditions":"Body Weight Changes, Human Immunodeficiency Virus, ART","enrollment":""},{"nctId":"NCT03272347","phase":"PHASE2","title":"Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-27","conditions":"HIV-1 Infection","enrollment":123},{"nctId":"NCT03332095","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT04429152","phase":"PHASE3","title":"ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance","status":"UNKNOWN","sponsor":"Professor Francois Venter","startDate":"2021-02-09","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT02629822","phase":"PHASE2","title":"Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-14","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Delstrigo","MK-1439A"],"phase":"marketed","status":"active","brandName":"DOR/3TC/TDF","genericName":"DOR/3TC/TDF","companyName":"Prism Health North Texas","companyId":"prism-health-north-texas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DOR/3TC/TDF is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: reverse transcriptase inhibition and nucleotide reverse transcriptase inhibition. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}